Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.47 |
| ▸ | MLYCD | O95822 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 5/20 | 0.44 |
| ▸ | TXK | P42681 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794239 | 0.83 | CA2 (0.52) | PGRMLYCDKMT2ANSD2 | |
| SCHEMBL15480654 | 0.83 | HDAC6 (0.72) | HDAC6HDAC1HDAC8 | |
| SCHEMBL12687869 | 0.82 | CA1 (0.57) | HDAC6HDAC1HDAC8MLYCDKMT2A | |
| Water SCHEMBL11222637 | 0.82 | PGR (0.50) | PGRMLYCDKMT2ANSD2 | |
| SCHEMBL4610487 | 0.81 | HDAC1 (0.61) | HDAC6HDAC1HDAC8KMT2A | |
| SCHEMBL4659080 | 0.81 | HDAC6 (0.67) | HDAC6HDAC1HDAC8 | |
| SCHEMBL4659287 | 0.81 | HDAC6 (0.67) | HDAC6HDAC1HDAC8 | |
| SCHEMBL15480652 | 0.81 | HDAC6 (0.56) | HDAC6HDAC1HDAC8KMT2A | |
| SCHEMBL29273240 | 0.81 | KMT2A (0.62) | PGRKMT2ANSD2 | |
| Water SCHEMBL11222627 | 0.81 | PGR (0.49) | PGRMLYCDKMT2ANSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC6 10/4885HDAC1 2/4885PGR 4016/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC6 10/4885HDAC1 2/4885PGR 4016/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC6 10/4885HDAC1 2/4885PGR 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.